Amoxicillin/clavulanic acid extra strength - GlaxoSmithKline

Drug Profile

Amoxicillin/clavulanic acid extra strength - GlaxoSmithKline

Alternative Names: Augmentin ES; Augmentin ES Chewable; Augmentin ES-600; Dry syrup formulation of Augmentin ES; Extra strength amoxicillin/clavulanate potassium - GSK; Extra-strength amoxicillin/clavulanic acid

Latest Information Update: 03 Feb 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antibacterials; Beta-lactams; Penicillins
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis media
  • Discontinued Rhinosinusitis

Most Recent Events

  • 03 Feb 2016 Discontinued - Phase-III for Rhinosinusitis (In adolescents, In children, In infants) in Japan (PO)
  • 01 Nov 2013 GlaxoSmithKline completes a phase III trial in Rhinosinusitis (in infants, children and adolescents) in Japan (NCT01934231)
  • 01 Aug 2013 Phase-III clinical trials in Rhinosinusitis (in infants, children and adolescents) in Japan (PO; powder for oral suspension)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top